ATLANTA and WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Trellis Rx, a leading technology-enabled specialty pharmacy services provider, today announced the integration of PrismRA®, a diagnostic blood test created by Scipher Medicine® that predicts non-response to TNF Inhibitor (TNFi) therapies, into its clinical pathway for patients living with rheumatoid arthritis (RA). Scipher Medicine, the manufacturer of PrismRA, is a precision immunology company helping providers determine the most effective therapy for their patients.